Molecular Formula | C22H21N3O3S |
Molar Mass | 407.49 |
Density | 1.31±0.1 g/cm3(Predicted) |
Melting Point | 216 °C(Solv: ethanol (64-17-5)) |
Boling Point | 622.9±65.0 °C(Predicted) |
Solubility | DMSO: ≥ 55 mg/mL |
Appearance | Yellow-white solid |
Color | white to beige |
pKa | 10.39±0.10(Predicted) |
Storage Condition | 2-8°C |
In vitro study | ML141 experience the ability of TMX to suppress BLBC cell growth through both. ML141 also significant protection neuroblastoma cells from metformin-induced apotosis. Moreover, ML141 diminishes K. pneumoniae invasion in a dose-dependent manner. ML141 enhances the ability of TMX to inhibit cell growth by inducing cell death and inhibiting cell division. ML141 also significantly protected neuroblastoma from metformin-induced apoptosis. In addition, ML141 dose-dependently reduced Klebsiella invasion by Pneumonia. |
In vivo study | In NOD/SCID mice bearing MDA-MB 231 derived waves, ML141 (1 mg/day I. p.), via inhibition of Cdc42, enabled TMX to suppress growth of MDA-MB 231 derived tumors. In addition, ML 141 (10 mg/kg I. p.) cultures G-CSF-induced hematopoetic stem and precursor cell mobilization in mice. In NOD/SCID mice loaded with MDA-MB tumors of 231 origin, ML141 (1 mg/day I. p.), by inhibiting Cdc42, TMX was able to inhibit the growth of MDA-MB 231 of the derived tumors. In addition, ML141 (10 mg/kg I. p.) enhanced G-CSF induced mobilization of hematopoietic stem and progenitor cells in mice. |
WGK Germany | 3 |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 2.454 ml | 12.27 ml | 24.541 ml |
5 mM | 0.491 ml | 2.454 ml | 4.908 ml |
10 mM | 0.245 ml | 1.227 ml | 2.454 ml |
5 mM | 0.049 ml | 0.245 ml | 0.491 ml |
biological activity | ML141 is an effective, selective reversible non-competitive inhibitor of Rho family GTPase cdc42, IC50 is 200 nM. ML141 (CID-2950007) is an effective, selective reversible non-competitive inhibitor of Rho family GTPase cdc42, IC50 is 200 nM. The cdc42 is more selective than the GTPases in other Rho families (such as Rac1, Rab2, Rab7). ML141 is associated with increased p38 activation and may induce p38-dependent apoptosis/senescence. ML141 also protects neuroblastoma cells from metformin (metformin)-induced apoptosis. |
in vitro study | ML141 enhances the ability of TMX to suppress BLBC cell growth through both induction of cell death and suppression of cell division. ML141 also significantly protects neuroblastoma cells from metformin-induced apoptosis. Moreover, ML141 diminishes K. pneumoniae invasion in a dose-dependent manner. ML141 induces cell death and inhibits cell division, enhance the ability of TMX to inhibit cell growth. ML141 also significantly protects neuroblastoma from metformin-induced apoptosis. In addition, ML141 dose-dependently reduced the invasion of Klebsiella pneumoniae. |
in vivo study | in NOD/SCID mice bearing MDA-MB 231 derived tumors, ML141 (1 mg/day I. p.), via inhibition of Cdc42, enables TMX to suppress growth of MDA-MB 231 derived tumors. in addition, ML141 (10 mg/kg I. p.) enhances G-CSF-induced hematopoietic stem and progenitor cell mobilization in mice. in NOD/SCID mice loaded with MDA-MB 231-derived tumors, ML141 (1 mg/day I. p.) can inhibit TMX from MDA-MB 231-derived tumors by inhibiting Cdc42. In addition, ML141 (10 mg/kg I. p.) enhanced G-CSF-induced mobilization of hematopoietic stem cells and progenitor cells in mice. |
target | TargetValue cdc42 () 200 nM |
Target | Value |
cdc42 () | 200 nM |